melanocortin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-15. Numbers and descriptions here follow the published literature rather than marketing material.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
== References == Books B Gaze and B Smith, Equality and Discrimination Law in Australia: An Introduction (2017) E McGaughey, A Casebook on Labour Law (Hart 2019) J Riley Munton, Labour Law: An Introduction to the Law of Work (OUP 2021) C Ronalds and E Raper, Discrimination Law and Practice (5th edn 2019) A Stewart, A Forsyth, M Irving, R Johnstone, S McCrystal, Creighton & Stewart's Labour Law (6th edn Federation 2016) Articles A Forsyth, 'There's one big reason wages are stagnating: the enterprise bargaining system is broken, and in terminal decline (June 1, 2022) The Conversation P Gahan, 'The Future of State Industrial Regulation: Can We Learn From Victoria?' (2005) Australian Review of Public Affairs D Hyslop and S Stillman, 'Youth minimum wage reform and the labour market' (March 2004) New Zealand Treasury Working Paper 04/03 R Owens, 'Unfinished constitutional business: building a national system to regulate work' (2009) 22 AJLL 258 E Schofield-Georgeson and J Riley Munton, 'Precarious work in the high court' (2023) 45(2) Sydney Law Review 219
== English translations == Robert Potter, 1781 - verse: full text Michael Wodhull, 1782 – verse Edward P. Coleridge, 1891 – prose: full text Theodore Alois Buckley, 1892 – prose: full text Gilbert Murray, 1912 – verse: full text Arthur S. Way, 1912 – verse F. L. Lucas, 1924 – verse Augustus T. Murray, 1931 – prose Countee Cullen, 1935 Moses Hadas and John McLean, 1936 – prose R. C. Trevelyan, 1939 – verse Rex Warner, 1944 – verse Robinson Jeffers, 1946 – verse Ray Mathew, 1953 – verse Peter D. Arnott, 1961 – verse Philip Vellacott, 1963 Rush Rehm, 1973 - prose John Davie, 1996 James Morwood, 1997 – prose Paul Roche, 1998 – verse Ruby Blondell, 1999 – verse George Theodoridis, 2004 – prose: full text Stephen Esposito, 2004 – verse Joseph Goodrich, 2005 – verse: full text Graham Kirby, 2006 – verse (The Bloomsbury Theatre) Diane Arnson Svarlien, 2008 – verse Robin Robertson, 2008 – verse J. Michael Walton, 2008 – prose Ian C. Johnston, 2008 – verse: full text Tom Paulin, 2010 - full text Judith Mossman (classicist), 2011 – prose Brian Vinero, 2012 – rhymed verse: full text Mike Bartlett, 2012 – play Diane Rayor, 2013 David Stuttard, 2014 – prose Alan Chriztopher R. Aranza, 2015 – prose Rachel Kitzinger, 2016 – verse Charles Martin, 2019 Dr. Richard W. Swanson, 2020 – prose Michael Ewans, 2022 – verse
The PC version received "mixed or average reviews" according to the review aggregation website Metacritic. In a review for IGN, critic Tal Blevins noted that Blue Shift's gameplay "is pretty much what we've come to expect out of Half-Life" by blending action and puzzle solving, stating that the latter "were all logical and well done, although some of the jumping puzzles were frustrating". Though IGN praised the game for maintaining the "epic" feel of the original, Blevins was critical of the relatively short length of the game. GameSpot reviewer Greg Kasavin agreed with many of IGN's criticisms, stating that "it's not that the game is easy so much that it's extremely short" and that Blue Shift "doesn't amount to much on its own terms". In addition, Kasavin described the graphical enhancements brought about by the High Definition pack as "helpful", but noted that "they still don't make Half-Life look like a new game—nor are many of the changes themselves very noticeable". Other reviews echoed complaints about the similarity of Blue Shift to previous games. GameSpy reviewer Jamie Madigan stated that "what really pulls the game down is the 'more of the same' factor". Although writing that the game "feels like just a few more levels for the original game", he noted that this is what Blue Shift was designed to be, given its origins as an add-on for a Dreamcast version of Half-Life. Madigan described the single-player campaign as "decent" and commented that the new graphics made the game "worthy of consideration".
The cooling trend since the mid-Holocene thermal maximum is consistent with ice core and pollen records, but the corresponding magnitude of cooling is elusive due to complicated influences from local effects such as humidity and soil water composition. The meaning of isotopes in cellulose and its applications is still an area of active study.
Sources: en.wikipedia.org
The chain of reactions that generate reactive oxygen species (ROS) results in oxidative stress, which ultimately causes cell damage. Type II pathway of photodynamic reaction: After PS is excited into T1 state, the energy is transferred directly between PS and O2. This interaction transforms the oxygen molecules into a highly reactive form known as singlet oxygen. Singlet oxygen possesses potent oxidizing properties, making it extremely effective in reacting with and damaging cellular components. However, this reaction is selective; while most cellular components exist in a less reactive singlet state and remain unaffected, the singlet oxygen specifically targets and reacts with oxygen molecules in the cell cytoplasm. PDT is used to treat cancer across diverse types and sites. A unique feature of PDT is that photosensitizers tend to accumulate more selectively in cancer cells than in normal cells. The high affinity of photosensitizers to low-density lipoprotein (LDL) allows for selectivity. LDL acts as a carrier, allowing photosensitizers to travel into cancerous tissues. The interaction between photosensitizers and LDL makes it easier for therapeutic agents to reach the right places, which makes PDT more effective against cancer.
The British Embassy in Pyongyang was closed temporarily from 27 May and all diplomatic staff left the country. According to a statement from the British Foreign Office, this was due to restrictions on entry to the country, making it a challenge to rotate staff and sustain the operation of the Embassy. On 19 June, an update to the WHO from the Ministry of Public Health affirmed that all the educational institutions in the country were now open. The underground network that assists defectors in escaping North Korea was reported as being almost unable to operate amidst the strict controls implemented to stop the virus, and defection attempts were largely suspended. Defection rates had been declining already, probably due to increased security under the administrations of Kim Jong Un in North Korea and Xi Jinping in China. Between the start of April and end of June 2020, only 12 North Korean defectors entered South Korea, compared with 320 during the same period in 2019.
=== 2014 FDA Form 483 === In December 2014 the FDA issued a Form 483 letter over concerns discovered during an inspection of its Srikakulam facility. No specific violations were mentioned in the letter.
The causative agent of yaws is Treponema pallidum pertenue, which is transmissible by direct physical contact between infected people. Yaws is not sexually transmitted, and occurs in tropical, humid environments of Africa, Pacific Islands, Asia and South America. Unlike syphilis, which displays vertical transmission, one strain of T. p. pertenue researched was not vertically transmissible in a guinea pig model, and yaws cannot be spread from mother to offspring. Yaws appears as skin lesions, usually papules, commonly on the lower extremities, but present in other areas such as the arms, trunk and hands. Three stages of yaws disease have been documented: primary yaws which presents as inflamed sores on the lower body, secondary yaws which presents as a variety of skin abnormalities along with bone inflammation, and tertiary yaws, also referred to as latent yaws, which occurs when T. p. pertenue is serologically detected in the host but no clinical signs are displayed until relapse, which often occurs years later. Yaws is treated with antibiotics such as azithromycin and benzathine penicillin-G.
Biological and chemical samples, in either liquid or solid state, are stored in vials, plates or tubes. Often, they need to be frozen and/or sealed to avoid contamination or to retain their biological and/or chemical properties. Specifically, the life science industry has standardized on a plate format, known as the microtiter plate, to store such samples. The microtiter plate standard was formalized by the Society for Biomolecular Screening in 1996. It typically has 96, 384 or even 1536 sample wells arranged in a 2:3 rectangular matrix. The standard governs well dimensions (e.g. diameter, spacing and depth) as well as plate properties (e.g. dimensions and rigidity). A number of companies have developed robots to specifically handle SBS microplates. Such robots may be liquid handlers which aspirates or dispenses liquid samples from and to these plates, or "plate movers" which transport them between instruments, such as robots from Opentrons. Other companies have pushed integration even further: on top of interfacing to the specific consumables used in biology, some robots (Andrew by Andrew Alliance, see picture) have been designed with the capability of interfacing to volumetric pipettes used by biologists and technical staff. Essentially, all the manual activity of liquid handling can be performed automatically, allowing humans spending their time in more conceptual activities. Instrument companies have designed plate readers which can carry out detect specific biological, chemical or physical events in samples stored in these plates.
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.